Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01241708 · OUTCOME

To Determine the Response Rate of Patients With Multiple Myeloma Treated With High-dose Melphalan or High-dose Melphalan in Combination With Bortezomib Given in Tandem Transplants.

Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma · Source last updated 2025-09-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
3 years

What was measured

Overall response rate of participants after completing tandem transplant. Overall Response rate defined as the composite endpoint of response to treatment which includes Complete Response (CR), Partial Response (PR), stable disease (SD) as defined in International Response Criteria.

Analysis population: 94 participant response assessed after completion of tandem transplant

Groups in this outcome

Tandem Transplantation With Melphalan and Bortezomib

Tandem autologous hematopoietic stem cell transplantation with melphalan followed by melphalan and bortezomib in patients with multiple myeloma Bortezomib: Bortezomib 1.6mg/m2 on day -4 and day -1

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Tandem Transplantation With Melphalan and Bortezomib94

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Tandem Transplantation With Melphalan and Bortezomib86Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        86
denoms
  1. counts
    1. group Id
      OG000
      value
      94
    units
    Participants
description
Overall response rate of participants after completing tandem transplant. Overall Response rate defined as the composite endpoint of response to treatment which includes Complete Response (CR), Partial Response (PR), stable disease (SD) as defined in International Response Criteria.
groups
  1. description
    Tandem autologous hematopoietic stem cell transplantation with melphalan followed by melphalan and bortezomib in patients with multiple myeloma Bortezomib: Bortezomib 1.6mg/m2 on day -4 and day -1
    id
    OG000
    title
    Tandem Transplantation With Melphalan and Bortezomib
param Type
COUNT_OF_PARTICIPANTS
population Description
94 participant response assessed after completion of tandem transplant
reporting Status
POSTED
time Frame
3 years
title
To Determine the Response Rate of Patients With Multiple Myeloma Treated With High-dose Melphalan or High-dose Melphalan in Combination With Bortezomib Given in Tandem Transplants.
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice